2-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide,
PF 03084014,
PF 3084014,
PF-03084014,
PF-3084014,
PF03084014,
PF3084014,
Nirogacestat,
PF-03084014,
1290543-63-3,
PF-3084014,
865773-15-5,
UNII-QZ62892OFJ,
PF 3084014,
QZ62892OFJ,
PF-03084014 (PF-3084014),
Z-3181,
(S)-2-(((S)-6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide,
Nirogacestat [USAN],
Nirogacestat (USAN/INN),
GTPL7746,
CHEMBL1770916,
SCHEMBL13184754,
DTXSID60235679,
EX-A855,
(2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide,
MFCD19980705,
s8018,
ZINC38217837,
AKOS030526383,
CS-1689,
DB12005,
SB16726,
NCGC00378713-01,
HY-15185,
FT-0700381,
pf-03084014-pf-3084014,
D10960,
Nirogacestat (PF-03084014, PF-3084014),
PF-03084014;PF-3084014;865773-15-5;,
(2S)-2-{[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino}-N-(1-{1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl}-1H-imidazol-4-yl)pentanamide,
(S)-2-((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-ylamino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide,
D00GPQ,
PF03084014,
PF3084014,
A3711,
PF 03084014,
A11259,
C550722,
(2S)-2-(6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-ylamino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)propanamide,
2-(5,7-difluoro-1,2,3,4-tetrahydronaphthalen-3-ylamino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide,
pentanamide, 2-[[(2s)-6,8-difluoro-1,2,3,4-tetrahydro-2-naphthalenyl]amino]-n-[1-[2-[(2,2-dimethylpropyl)amino]-1,1-dimethylethyl]-1h-imidazol-4-yl]-, (2s)-,